Citations

Clear

3314 citation(s) found for "Yu, Alexander".

Self‐reported physical activity and gait in older adults without dementia: A longitudinal study
Krell‐Roesch, Janina , Syrjanen, Jeremy A. , Moeller, Tobias , Krafft, Jelena , Barisch‐Fritz, Bettina , Kremers, Walter K. , Ali, Farwa, Petersen, Ronald , Vassilaki, Maria , Geda, Yonas E. , Vassilaki, Maria , Geda, Yonas E , Kremers, Walter K , Ali, Farwa , Knopman, David S. , Stein, Thorsten , Wöll, Alexander

Mayo Clinic

Health Science Reports | November 6, 2024 | Volume: 7 | Issue: 11 | Pages: No page available

10.1002/hsr2.70108 | PMID 39507676 Get It

AbstractBackground and AimsPhysical activity (PA) is associated with higher gait speed. We aimed to examine the associations between PA and change in spatial and temporal gait measures as well as fall risk in community‐dwelling individuals free of dementia.MethodsLongitudinal study among 4173 individuals aged ≥50 years (mean age 71 years; 2078 males; median follow‐up 4 years) enrolled in the Mayo Clinic Study of Aging. Self‐reported late‐life PA was used to calculate overall PA and moderate‐vigorous PA (MVPA) scores. Gait was assessed using GAITRite® and Zeno™ systems. Incident falls information was based on diagnostic codes retrieved from medical records. We ran linear mixed effects models to examine associations between z‐scored PA variables and longitudinal gait parameters, adjusted for age, sex, education, body mass index (BMI), medical comorbidities, and including interactions between PA and time since baseline. In secondary analyses, we calculated Cox Proportional hazard models with age as time scale predicting incident falls by PA, adjusting for sex, education, BMI, medical comorbidities, and falls history.ResultsAt baseline, higher PA was associated with higher velocity (overall PA: estimate 2.9935; MVPA: 2.2961; p < 0.001), higher cadence (overall PA: 1.0665; MVPA: 0.9073; p < 0.001), greater stride length (overall PA: 2.0805; MVPA: 1.4726; p < 0.001), shorter double support time (overall PA: −0.0257; MVPA: −0.0205; p < 0.001), and lower stance time variability (overall PA: −0.0204, p < 0.001; MVPA: −0.0152; p = 0.006). Overall PA was longitudinally associated with less decline in cadence, and MVPA with less increase in intraindividual stance time variability. Overall PA (Hazard ratio 0.892, 95% confidence interval 0.828–0.961, p = 0.003) and MVPA (HR 0.901; 95% CI 0.835–0.973, p = 0.008) were associated with a decreased risk of incident falls.ConclusionLate‐life PA was associated with favorable gait outcomes and decreased risk of incident falls. Thus, late‐life PA may help to maintain gait performance and decrease fall risk in old age.
Surgical Predictors of Clinical Outcome 6 Years After Revision ACL Reconstruction
Group, The MARS, Wright, Rick W. , Huston, Laura J. , Haas, Amanda K. , Cooper, Daniel E. , Dunn, Warren R. , Lantz, Brett A., Amendola, Annunziato , Annunziata, Christopher C., Arciero, Robert A. , Bach, Bernard R. , Baker, Champ L., Bartolozzi, Arthur R. , Baumgarten, Keith M. , Berg, Jeffrey H., Bernas, Geoffrey A., Brockmeier, Stephen F. , Bush‐Joseph, Charles A., Butler, J. Brad, Carey, James L. , Carpenter, James E. , Cole, Brian J. , Cooper, Jonathan M., Creighton, R. Alexander , Flanigan, David C. , Frederick, Robert W., Ganley, Theodore J. , Gatt, Charles J. , Gecha, Steven R., Hame, Sharon L. , Hannafin, Jo A., Harner, Christopher D. , Harris, Norman Lindsay, Hechtman, Keith S., Hershman, Elliott B., Hoellrich, Rudolf G., Johnson, David C. , Kaeding, Christopher C., Kamath, Ganesh V. , Klootwyk, Thomas E., Levy, Bruce A. , Benjamin, C. , Maiers, G. Peter, Marx, Robert G. , Matava, Matthew J. , Mathien, Gregory M., McCormack, Robert G. , Miller, Bruce S., Nissen, Carl W. , O’Neill, Daniel F., Parker, Richard D., Purnell, Mark L., Ramappa, Arun J. , Rauh, Michael A. , Rettig, Arthur C., Sekiya, Jon K., Shea, Kevin G. , Slauterbeck, James R., Smith, Matthew V. , Svoboda, Steven J. , Taft, Timothy N., Tenuta, Joachim J., Tingstad, Edwin M., Vidal, Armando F. , Viskontas, Darius G., White, Richard A., Wolcott, Michelle L., York, James J. , Group, The MARS, Pennings, Jacquelyn S. , Allen, Christina R. , DeBerardino, Thomas M. , Spindler, Kurt P , Stuart, Michael J. , Brophy, Robert H. , Cox, Charles L. , David, Tal S. , Giffin, J. Robert , Johnson, David C., Johnson, Timothy S. , Jones, Morgan H. , Kaeding, Christopher C. , McAllister, David R. , McCarty, Eric C. , Miller, Bruce S., Owens, Brett D. , Sherman, Orrin H. , Spang, Jeffrey T. , Vidal, Armando F. , Williams, James S. , Wolf, Brian R.

Mayo Clinic

The American Journal of Sports Medicine | November 6, 2024 | Volume: 52 | Issue: 13 | Pages: 3286-3294

10.1177/03635465241288227 | PMID 39503722 Get It

Background: Revision anterior cruciate ligament (ACL) reconstruction has been documented to have inferior outcomes compared with primary ACL reconstruction. The reasons why remain unknown. Purpose: To determine whether surgical factors performed at the time of revision ACL reconstruction can influence a patient’s outcome at 6-year follow-up. Study Design: Cohort study; Level of evidence, 2. Methods: Patients who underwent revision ACL reconstruction were identified and prospectively enrolled between 2006 and 2011. Data collected included baseline patient characteristics, surgical technique and pathology, and a series of validated patient-reported outcome instruments: Knee injury and Osteoarthritis Outcome Score (KOOS), International Knee Documentation Committee (IKDC) subjective form, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and Marx activity rating score. Patients were followed up for 6 years and asked to complete the identical set of outcome instruments. Regression analysis was used to control for baseline patient characteristics and surgical variables to assess the surgical risk factors for clinical outcomes 6 years after surgery. Results: A total of 1234 patients were enrolled (716 men, 58%; median age, 26 years), and 6-year follow-up was obtained on 79% of patients (980/1234). Using an interference screw for femoral fixation compared with a cross-pin resulted in significantly better outcomes in 6-year IKDC scores (odds ratio [OR], 2.2; 95% CI, 1.2-3.9; P = .008) and KOOS sports/recreation and quality of life subscale scores (OR range, 2.2-2.7; 95% CI, 1.2-4.8; P < .01). Use of an interference screw compared with a cross-pin resulted in a 2.6 times less likely chance of having a subsequent surgery within 6 years. Use of an interference screw for tibial fixation compared with any combination of tibial fixation techniques resulted in significantly improved scores for IKDC (OR, 1.96; 95% CI, 1.3-2.9; P = .001); KOOS pain, activities of daily living, and sports/recreation subscales (OR range, 1.5-1.6; 95% CI, 1.0-2.4; P < .05); and WOMAC pain and activities of daily living subscales (OR range, 1.5-1.8; 95% CI, 1.0-2.7; P < .05). Use of a transtibial surgical approach compared with an anteromedial portal approach resulted in significantly improved KOOS pain and quality of life subscale scores at 6 years (OR, 1.5; 95% CI, 1.02-2.2; P≤ .04). Conclusion: There are surgical variables at the time of ACL revision that can modify clinical outcomes at 6 years. Opting for a transtibial surgical approach and choosing an interference screw for femoral and tibial fixation improved patients’ odds of having a significantly better 6-year clinical outcome in this cohort.
The Combined Inhibition of SREBP and mTORC1 Signaling Synergistically Inhibits B‐Cell Lymphoma
Zhu, Zhenhan, Jiang, Wenxia , Zhou, Jiehao , Maldeney, Alexander R. , Liang, Jingru , Luo, Wei , Luo, Wei , Zhu, Zhenhan, Yang, Jing

Mayo Clinic

Cancer Medicine | November 6, 2024 | Volume: 13 | Issue: 21 | Pages: No page available

10.1002/cam4.70342 | PMID 39501600 Get It

ABSTRACT Background The sterol regulatory element‐binding protein (SREBP) pathway is essential for maintaining sterol homeostasis during B cell activation and germinal center B cell proliferation. However, its potential as a therapeutic target to treat B‐cell lymphoma remains unclear. Methods We examined SREBP protein expression in human B‐cell lymphoma samples using immunohistochemistry. Additionally, we conducted in vitro studies using SREBP signaling inhibitors in combination with rapamycin to assess their effects on cell proliferation and lipid metabolism in B‐cell lymphoma cells. Results Our analysis revealed high levels of SREBP2 protein expression in human B‐cell lymphoma samples. Inhibiting SREBP signaling or its downstream target HMG‐CoA reductase (HMGCR) with Fatostatin or Simvastatin effectively suppressed B‐cell lymphoma cell proliferation. However, B‐cell lymphoma cells responded to statin treatment by activating the mTORC1‐pS6 pathway, suggesting a compensatory mechanism to overcome statin‐induced cell cycle arrest. Combining low‐dose statin treatment with the mTOR inhibitor rapamycin produced a synergistic effect, significantly inhibiting B‐cell lymphoma proliferation, cell cycle progression, and lipid raft formation. Conclusions These results highlight the potential of a combined therapeutic approach targeting both SREBP and mTORC1 as a novel strategy for treating B‐cell lymphoma.
Multicenter validation of an RNA-based assay to predict anti-PD-1 disease control in patients with recurrent or metastatic head and neck squamous cell carcinoma: the PREDAPT study
Flanagan, Kevin C. , Earls, Jon, Hiken, Jeffrey, Wellinghoff, Rachel L., Ponder, Michelle, McLeod, Howard L. , Westra, William H. , Vavinskaya, Vera , Sutton, Leisa , Deichaite, Ida , Macdonald, O. Kenneth, Welaya, Karim, Wade, James L. , Azzi, Georges, Pippas, Andrew W., Slim, Jennifer N. , Bank, Bruce, Sui, Xingwei, Kossman, Steven E., Shenkenberg, Todd D., Alexander, Warren L., Price, Katharine A. , Messina, D. , Glasscock, Jarret , Adkins, Douglas, Ley, Jessica C. , Colevas, Alexander Dimitrios , Cohen, Ezra E.W. , Duncavage, Eric James

Mayo Clinic

Journal for ImmunoTherapy of Cancer | November 3, 2024 | Volume: 12 | Issue: 11 | Pages: e009573

10.1136/jitc-2024-009573 | PMID 39489541 Get It

Background Despite advances in cancer care and detection, >65% of patients with squamous cell cancer of the head and neck (HNSCC) will develop recurrent and/or metastatic disease. The prognosis for these patients is poor with a 5-year overall survival of 39%. Recent treatment advances in immunotherapy, including immune checkpoint inhibitors like pembrolizumab and nivolumab, have resulted in clinical benefit in a subset of patients. There is a critical clinical need to identify patients who benefit from these antiprogrammed cell death protein 1 (anti-PD-1) immune checkpoint inhibitors. Methods Here, we report findings from a multicenter observational study, PREDicting immunotherapy efficacy from Analysis of Pre-treatment Tumor biopsies (PREDAPT), conducted across 17 US healthcare systems. PREDAPT aimed to validate OncoPrism-HNSCC, a clinical biomarker assay predictive of disease control in patients with recurrent or metastatic HNSCC treated with anti-PD-1 immune checkpoint inhibitors as a single agent (monotherapy) and in combination with chemotherapy (chemo-immunotherapy). The test used RNA-sequencing data and machine learning models to score each patient and place them into groups of low, medium, or high. Results The OncoPrism-HNSCC prediction significantly correlated with disease control in both the monotherapy cohort (n=62, p=0.004) and the chemo-immunotherapy cohort (n=50, p=0.01). OncoPrism-HNSCC also significantly predicted progression-free survival in both cohorts (p=0.015 and p=0.037, respectively). OncoPrism-HNSCC had more than threefold higher specificity than programmed death-ligand 1 combined positive score and nearly fourfold higher sensitivity than tumor mutational burden for predicting disease control. Conclusions Here, we demonstrate the clinical validity of the OncoPrism-HNSCC assay in identifying patients with disease control in response to anti-PD-1 immune checkpoint inhibitors. Trial registration number NCT04510129.
Immunological and molecular features of the tumor microenvironment of long-term survivors of ovarian cancer
Hamilton, Phineas T. , Phung, Minh Tung , Stevens, Donald L.I., Kalaria, Shreena , Laumont, Céline M. , Moss, Elena, Alimujiang, Aliya , Meagher, Nicola S. , Hendley, Joy , Goode, Ellen L. , Shen, Hui , Richardson, Jean , Deurloo, Cindy McKinnon, Chase, Anne, Grout, Bronwyn, Cushing‐Haugen, Kara L. , Anglesio, Michael S. , Huntsman, David G. , Talhouk, Aline , Hanley, Gillian E. , Alsop, Jennifer , Jimenez-Linan, Mercedes , Boros, Jessica , Brand, Alison H. , Sharma, Raghwa , Hecht, Jonathan L. , Sasamoto, Naoko , Terry, Kathryn L. , Lester, Jenny, Carney, Michael E. , Goodman, Marc T. , Fasching, Peter A., Bisinotto, Christiani, Le, Nhu D. , Menon, Usha , García, María J. , Rodríguez‐Antona, Cristina , Farrington, Kyo , Kelemen, Linda E. , Kommoss, Stefan , Staebler, Annette , Garsed, Dale W. , Piskorz, Anna , Bowtell, David D.L. , Ramus, Susan J. , Pike, Malcolm C., Pearce, Celeste Leigh , Ramus, Susan J , Rodríguez-Antona, Cristina , Menon, Usha , Anglesio, Michael S , Brand, Alison H , Bowtell, David D , Garsed, Dale W , Goodman, Marc T , Phung, Minh Tung , Nelson, Brad H. , Milne, Katy , Harris, Bronwyn, Thornton, Shelby , Singh, Karanvir , Bolithon, Adelyn , Fereday, Sián , Kennedy, Catherine J. , Ariyaratne, Dinuka , Alsop, Kathryn , Traficante, Nadia , Karnezis, Anthony N. , Chase, Anne, Doherty, Jennifer A. , Harris, Holly R. , Heinze, Karolin , Pharoah, Paul D.P. , Harnett, Paul R. , Karlan, Beth Y. , Hernandez, Brenda Y. , Wilkens, Lynne R. , Behrens, Sabine , Fortner, Renée T. , Reis, Francisco José Cândido dos , Ghatage, Prafull , Köbel, Martin , Elishaev, Esther , Modugno, Francesmary , Cook, Linda S. , Gentry‐Maharaj, Aleksandra , Brenton, James D. , DeFazio, Anna

Mayo Clinic

Journal of Clinical Investigation | October 29, 2024 | Volume: 134 | Issue: 24 | Pages: No page available

10.1172/jci179501 | PMID 39470729 Get It

BACKGROUND Despite an overall poor prognosis, about 15% of patients with advanced-stage tubo-ovarian high-grade serous carcinoma (HGSC) survive 10 or more years after standard treatment. METHODS We evaluated the tumor microenvironment of this exceptional, understudied group using a large international cohort enriched for long-term survivors (LTS; 10+ years; n = 374) compared with mid-term (MTS; 5–7.99 years; n = 433) and short-term survivors (STS; 2–4.99 years; n = 416). Primary tumor samples were immunostained and scored for intraepithelial and intrastromal densities of 10 immune-cell subsets (including T cells, B cells, plasma cells, myeloid cells, PD-1 + cells, and PD-L1 + cells) and epithelial content. RESULTS Positive associations with LTS compared with STS were seen for 9 of 10 immune-cell subsets. In particular, the combination of intraepithelial CD8 + T cells and intrastromal B cells showed near 5-fold increased odds of LTS compared with STS. All of these associations were stronger in tumors with high epithelial content and/or the C4/Differentiated molecular subtype, despite immune-cell densities generally being higher in tumors with low epithelial content and/or the C2/Immunoreactive molecular subtype. CONCLUSION The tumor microenvironment of HGSC LTS is distinguished by the intersection of T and B cell coinfiltration, high epithelial content, and C4/differentiated molecular subtype, features which may inspire new approaches to immunotherapy. FUNDING Ovarian Cancer Research Program (OCRP) of the Congressionally Directed Medical Research Program (CDMRP), U.S. Department of Defense (DOD); American Cancer Society; BC Cancer Foundation; Canada’s Networks of Centres of Excellence; Canadian Cancer Society; Canadian Institutes of Health Research; Cancer Councils of New South Wales, Victoria, Queensland, South Australia, and Tasmania, Cancer Foundation of Western Australia; Cancer Institute NSW; Cancer Research UK; Deutsche Forschungsgesellschaft; ELAN Funds of the University of Erlangen-Nuremberg; Fred C. and Katherine B. Andersen Foundation; Genome BC; German Cancer Research Center; German Federal Ministry of Education and Research, Programme of Clinical Biomedical Research; Instituto de Salud Carlos III; Mayo Foundation; Minnesota Ovarian Cancer Alliance; Ministerio de Economía y Competitividad; Medical Research Council (MRC); National Center for Advancing Translational Sciences; National Health and Medical Research Council of Australia (NHMRC); Ovarian Cancer Australia; Peter MacCallum Foundation; Sydney West Translational Cancer Research Centre; Terry Fox Research Institute; The Eve Appeal (The Oak Foundation); UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge; University of Pittsburgh School of Medicine; U.S. National Cancer Institute of the National Institutes of Health; VGH & UBC Hospital Foundation; Victorian Cancer Agency.
Fewer Podocytes Associate with Progressive CKD Independent of Glomerular Volume and Nephrosclerosis or Clinical Characteristics
Kumar, Mahesh, Aperna, Fnu, Shaik, Afsana Ansari, Alexander, Mariam P., Đenić, Aleksandar , Shaik, Afsana Ansari, Mullan, Aidan F. , Hodgin, Jeffrey B. , Rule, Andrew D.

Mayo Clinic

Journal of the American Society of Nephrology | October 28, 2024 | Volume: 35 | Issue: 10S | Pages: No page available

10.1681/asn.2024pqpwkega Get It

Individuals Heterozygous for SLC34A3 Predicted Pathogenic Variants Are at Increased Risk of Nephrolithiasis
Chang, Alex R. , Cogal, Andrea G. , Frank, Jacob A., Scheinman, Steven J., Ma, Jun , Chang, Alexander R , Moore, Bryn S. , Luo, Jonathan Z. , Bucaloiu, Ion Dan , McDonnell, Shannon K. , Harris, Peter C. , Lieske, John C.

Mayo Clinic

Journal of the American Society of Nephrology | October 28, 2024 | Volume: 35 | Issue: 10S | Pages: No page available

10.1681/asn.20242524yrwv Get It

Invasive hemodynamic response to exercise in hemodynamically significant aortic stenosis with preserved left ventricular ejection fraction
Ali, Mays T. , Moeller, J E, Chemnitz, Alexander , Haujir, Amal , Oevrehus, K A, Haujir, Amal , Frederiksen, Peter , Mortensen, Nils Sofus Borg , Poulsen, Mikael Kjær , Pibarot, Phillippe , Pellikka, Patricia A. , Clavel, Marie‐Annick , Dahl, Jordi S.

Mayo Clinic

European Heart Journal | October 28, 2024 | Volume: 45 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehae666.1898 Get It

Abstract Background Guidelines acknowledge that discordant low-gradient (LG) aortic stenosis (AS) may be severe, but verifying this can be challenging. Right heart catheterization during exercise is considered the gold standard evaluating ventricular hemodynamics. No invasive studies have compared the hemodynamic response of discordant LG and severe AS during exercise. Purpose To describe exercise hemodynamics in patients with asymptomatic discordant AS and left ventricular ejection fraction ≥50%, and to identify the variables associated with the steepness of the pulmonary capillary wedge pressure (PCWP)/cardiac output (CO) slope defined as (peak exercise PCWP-rest PCWP)/(peak exercise CO-rest CO). Methods Patients with aortic valve area (AVA) ≤1.5 cm² underwent right heart catheterization at rest and during maximal exercise measuring pulmonary artery pressures, PCWP, CO and PCWP/CO slope. Patients were stratified in three groups: 1) discordant LG AS (AVA ≤1.0 cm² and mean gradient &lt;40 mmHg); 2) moderate AS (AVA &gt;1.0 cm²) and 3) high-gradient severe AS (AVA ≤1.0 cm² and mean gradient ≥40 mmHg). Results Among 86 patients, 17 (20%) had discordant LG, 49 (57%) moderate, and 20 (23%) high-gradient severe AS. The PCWP/CO slope was significantly steeper in discordant LG: median 3.3 mmHg/L/min (interquartile range: 2.2 mmHg/L/min) and high-gradient severe AS: 2.7 mmHg/L/min (1.5 mmHg/L/min) compared to moderate AS: 1.9 mmHg/L/min (2.0 mmHg/L/min), p=0.004. In a linear regression model adjusted for age, sex and rest PCWP, systemic arterial compliance and AS severity were significantly associated with the PCWP/CO slope. Furthermore, patients with discordant LG AS had a leftward and upward shift in the PCWP/CO slope. Conclusions Discordant LG and high-gradient severe AS had similar hemodynamic response to exercise with steeper PCWP/CO slope than in moderate AS, suggesting that discordant LG AS is a severe form of AS. In addition, the left-upward shift in PCWP/CO slope for discordant LG compared to high-gradient severe AS indicates that, this group also has latent heart failure with preserved ejection fraction physiology.
A cohort study examining predictors of stroke and bleeding among people with congenital heart disease and atrial fibrillation
O’Shea, Molly , Ravi, Sandhya, Ligten, Matthew Van, Ibrahim, Amna , Wang, Wen‐Yen, Alozie, Nneoma, Girardo, Marlene , Egbe, Alexander C. , Karikalan, Suganya Arunachalam , Baqal, Omar J , Bacon, Andrew K. , Smyth, P, Marshall, C, Egbe, Alexander C. , Majdalany, David S , Masry, Hicham El

Mayo Clinic

European Heart Journal | October 28, 2024 | Volume: 45 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehae666.2150 Get It

Abstract Background Congenital Heart Disease (CHD) is associated with development of atrial fibrillation (AF) at an early age. With increased survival of this cohort into adulthood, the prevalence of concurrent CHD and AF is expected to increase over the next several decades. Little is known about the utility of clinical risk factors or prediction models in determining bleeding or stroke rates in adults with CHD and AF. Purpose This study aims to measure the performance of the CHADSVASC and HASBLED scores in a cohort of people with CHD. The association between traditional stroke and bleeding risk factors, as well as CHD-specific factors, will be quantified. Methods Patients age 18 or older attending one of three centers in the USA were included in this study if they had a history of AF on ECG, holter monitor or device interrogation, in addition to a diagnosis of Tetralogy of Fallot (TOF), Double Outlet Right Ventricle (DORV), or Pulmonary Atresia with Intact Ventricular Septum (PA-IVS). Outcomes were major bleeding event, and stroke rate. Analysis was conducted using cox univariable regression controlling for current age. Receiver operator curve and c-statistics were produced for the CHADSVASC and HASBLED scores respectively. Results 326 people were included in this study, of whom 161 (49.5%) had TOF secondary to Pulmonic Stenosis, 126 (38.8%) had TOF secondary to Pulmonary Atresia, 25 (7.7%) had DORV, and 155 (47.7%) had PA-IVS. 227 people used warfarin (79.4%), 28 (9.8%) used apixaban, 9 (3.1%) used Rivaroxaban, 3 (1%) used Edoxaban, and 5 (1.7%) used Enoxaparin for a period of at least 30 days during the study. 13 (4.5%) people didn’t receive anticoagulation during the study. 26 people had a stroke (8.8%) while 85 people (28.6%) had a major bleeding event. Only the CHADSVASC score was significantly associated with stroke rates (HR 2.103, 95% CI 1.555 to 2.844, p&lt;0.001). Clinical variables, such as subtype of CHD, prior conduit placement or unifocalization were not associated with stroke or major bleeding events. C-statistic for the CHADSVASC score in predicting stroke events was 0.755 (Figure 1). C-statistic for the HASBLED score in predicting major bleeding was 0.442 (Figure 2). Conclusions Among people with CHD and AF, the CHADSVASC score can robustly predict stroke events. Other clinical variables are less valuable in predicting either bleeding or strokes. The HASBLED score likely doesn’t have a role in predicting major bleeding episodes in this cohort.